EGFR and non-small cell lung carcinoma: Osimertinib for instance is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that binds to certain mutant forms of EGFR that predominate in non-small cell lung cancer (NSCLC) tumors [5].